Security
SYNLOGIC INC Common Stock · SYBX
SYBXOTCCommon stockCurrentCIK 1527599Updated Oct 6, 2026
Name history
Mirna Therapeutics, Inc. · through Aug 25, 2017
SYBX price & chart
Loading TradingView…
OTC:SYBX on TradingView ↗About the company
Synlogic is a biopharmaceutical company historically focused on advancing novel therapeutics to transform the care of serious disease in need of new treatment options.
In the news
No coverage from other publishers is available.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 16,555,000Source | 20,755,000Source | 13,478,000Source | 17,370,000Source | 21,635,000Source | 14,611,000Source | 17,966,000Source | 36,057,000Source | 15,447,000Source | 19,826,000Source | 75,550,000Source | 110,865,000Source |
| Property, Plant and Equipment, NetUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 5,603,000Source | 7,323,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,591,000Source | 19,389,000Source | 13,183,000Source | 17,027,000Source | 19,966,000Source | 14,105,000Source | 17,271,000Source | 24,822,000Source | 14,668,000Source | 18,860,000Source | 23,960,000Source | 15,861,000Source |
| Assets, CurrentUSD | 16,505,000Source | 20,705,000Source | 13,428,000Source | 17,320,000Source | 21,573,000Source | 14,561,000Source | 17,916,000Source | 34,946,000Source | 15,397,000Source | 19,776,000Source | 49,907,000Source | 79,782,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 914,000Source | 1,230,000Source | 245,000Source | 293,000Source | 1,491,000Source | 456,000Source | 559,000Source | 2,429,000Source | 729,000Source | 830,000Source | 2,161,000Source | 2,153,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 12,102,000Source | 14,356,000Source |
| Other Assets, NoncurrentUSD | — | 0Source | — | — | 12,000Source | — | — | 14,000Source | — | 0Source | 16,000Source | 7,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 12,000Source | 12,000Source | 12,000Source | 12,000Source | 12,000Source | 12,000Source | 12,000Source | 12,000Source | 12,000Source | 12,000Source | 10,000Source | 71,000Source |
| Retained Earnings (Accumulated Deficit)USD | -444,164,000Source | -440,937,000Source | -442,518,000Source | -441,863,000Source | -443,853,000Source | -441,975,000Source | -441,334,000Source | -445,865,000Source | -442,656,000Source | -441,651,000Source | -414,301,000Source | -357,019,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 0Source | 0Source | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 6,000Source | -161,000Source |
| Stockholders' Equity Attributable to ParentUSD | 10,325,000Source | 13,108,000Source | 12,017,000Source | 12,593,000Source | 13,124,000Source | 12,554,000Source | 13,093,000Source | 9,399,000Source | 11,863,000Source | 12,751,000Source | 42,655,000Source | 82,610,000Source |
| Additional Paid in Capital, Common StockUSD | 456,995,000Source | 456,551,000Source | 457,041,000Source | 456,962,000Source | 462,342,000Source | 457,035,000Source | 456,933,000Source | 461,696,000Source | 457,025,000Source | 456,908,000Source | 459,458,000Source | 442,237,000Source |
| Liabilities and EquityUSD | 16,555,000Source | 20,755,000Source | 13,478,000Source | 17,370,000Source | 21,635,000Source | 14,611,000Source | 17,966,000Source | 36,057,000Source | 15,447,000Source | 19,826,000Source | 75,550,000Source | 110,865,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,230,000Source | 7,647,000Source | 1,461,000Source | 4,777,000Source | 5,652,000Source | 2,057,000Source | 4,873,000Source | 10,940,000Source | 3,584,000Source | 7,075,000Source | 20,404,000Source | 12,122,000Source |
| Operating Lease, Liability, CurrentUSD | — | 0Source | — | — | 0Source | — | — | 2,671,000Source | — | 0Source | 4,780,000Source | 4,152,000Source |
| Accounts Payable, CurrentUSD | 107,000Source | 178,000Source | 80,000Source | 45,000Source | 126,000Source | 206,000Source | 80,000Source | 719,000Source | 103,000Source | 164,000Source | 1,457,000Source | 1,785,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | — | — | 0Source | — | — | 11,792,000Source | — | 0Source | 12,491,000Source | 16,129,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 858,000Source | 1,756,000Source | 1,036,000Source | 952,000Source | 2,297,000Source | 1,157,000Source | 946,000Source | 3,116,000Source | 915,000Source | 2,037,000Source | 3,000,000Source | 5,290,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 15,600,000Source | 19,400,000Source | 13,200,000Source | 17,000,000Source | 20,000,000Source | 14,100,000Source | 17,300,000Source | 32,300,000Source | 14,700,000Source | 18,900,000Source | 47.7Source | 77,600,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 681,000Source | 317,000Source | -1,005,000Source | -23,359,000Source | -57,282,000Source | -66,147,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 33,000Source | 102,000Source | 6,000Source | 29,000Source | 10,000Source | 25,000Source | 117,000Source | 3,169,000Source | 2,806,000Source | 3,639,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -563,000Source | -1,601,000Source | -4,359,000Source | -31,658,000Source | -51,614,000Source | -56,888,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 12,000Source | 167,000Source | 25,339,000Source | 38,769,000Source | 58,351,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 0Source | 0Source | 14,000Source | 214,000Source | 728,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 0Source | 172,000Source | 20,944,000Source | -2,040,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -563,000Source | -1,589,000Source | -4,192,000Source | -6,147,000Source | 8,099,000Source | -577,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,000Source | 2,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 0Source | 5,000Source | 14,000Source | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 33,000Source | 102,000Source | 6,000Source | 29,000Source | 10,000Source | 25,000Source | 117,000Source | 3,169,000Source | 2,806,000Source | 3,639,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 15,600,000Source | 19,400,000Source | 13,200,000Source | 17,000,000Source | 14,100,000Source | 17,300,000Source | 14,700,000Source | 18,900,000Source | 47.7Source | 77,600,000Source |
| DepreciationUSD | — | — | — | — | — | — | — | 0Source | 0Source | 347,000Source | 1,958,000Source | 2,520,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | — | — | — | — | — | — | 0Source | 12,000Source | 81,000Source | 1,160,000Source | 11,000Source | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | 10,000Source | 80,000Source | 1,200,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 0Source | 0Source | — | 70,000Source | — | 10,000Source | 80,000Source | 1,200,000Source | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | — | — | — | — | — | — | 0Source | 0Source | 3,271,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 818,000Source | 1,165,000Source | 828,000Source | 800,000Source | 1,064,000Source | 836,000Source | 3,489,000Source | 6,631,000Source | 14,561,000Source | 16,555,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 5,000Source | 14,000Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | — | 0Source | — | — | — | — | — | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,301,000Source | -117,000Source | -543,000Source | -529,000Source | 681,000Source | 317,000Source | -1,005,000Source | -23,359,000Source | -57,282,000Source | -66,147,000Source |
| Nonoperating Income (Expense)USD | — | — | -1,310,000Source | 631,000Source | 469,000Source | 248,000Source | 2,000,000Source | 1,215,000Source | 3,003,000Source | 17,596,000Source | -2,107,000Source | 1,272,000Source |
| Operating ExpensesUSD | — | — | 991,000Source | 748,000Source | 1,012,000Source | 777,000Source | 1,319,000Source | 898,000Source | 4,008,000Source | 40,958,000Source | 58,532,000Source | 68,599,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | 0Source | 0Source | 9,571,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 1,000Source | — | 0Source | — | 0Source | 0Source | -2,000Source | -517,000Source | 7,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Restructuring Costs and Asset Impairment Charges | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 8,000Source | 3,371,000Source | 1,180,000Source |
| Operating Income (Loss)USD | — | — | -991,000Source | -748,000Source | -1,012,000Source | -777,000Source | -1,319,000Source | -898,000Source | -4,008,000Source | -40,950,000Source | -55,161,000Source | -67,419,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 1,000Source | — | 0Source | — | 0Source | 0Source | -2,000Source | -517,000Source | 7,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -2,301,000Source | -117,000Source | — | -529,000Source | — | — | -1,005,000Source | -23,354,000Source | -57,268,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | — | 0Source | — | — | 0Source | 5,000Source | 14,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,301,000Source | -117,000Source | -543,000Source | -529,000Source | 681,000Source | 317,000Source | -1,005,000Source | -23,359,000Source | -57,282,000Source | -66,147,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.19Source | -0.01Source | -0.04Source | -0.04Source | 0.05Source | 0.03Source | -0.08Source | -1.92Source | -8.81Source | -0.92Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.19Source | -0.01Source | -0.04Source | -0.04Source | 0.05Source | 0.03Source | -0.08Source | -1.92Source | -8.81Source | -0.92Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 12,319,212Source | 12,223,922Source | 12,418,592Source | 12,319,147Source | 12,394,912Source | 12,283,543Source | 12,311,909Source | 12,196,209Source | 6,502,279Source | 71,725,479Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 12,319,212Source | 12,223,922Source | 12,418,592Source | 12,319,147Source | 12,398,525Source | 12,388,595Source | 12,311,909Source | 12,196,209Source | 6,502,279Source | 71,725,479Source |
| Interest Expense (non-operating)USD | — | — | — | 0Source | — | — | — | — | — | 0Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 818,000Source | 1,165,000Source | 828,000Source | 800,000Source | 1,064,000Source | 836,000Source | 3,489,000Source | 6,631,000Source | 14,561,000Source | 16,555,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 1,000Source | 2,000Source |
| Nonoperating Income (Expense)USD | — | — | -1,310,000Source | 631,000Source | 469,000Source | 248,000Source | 2,000,000Source | 1,215,000Source | 3,003,000Source | 17,596,000Source | -2,107,000Source | 1,272,000Source |
| Operating ExpensesUSD | — | — | 991,000Source | 748,000Source | 1,012,000Source | 777,000Source | 1,319,000Source | 898,000Source | 4,008,000Source | 40,958,000Source | 58,532,000Source | 68,599,000Source |
| Research and Development ExpenseUSD | — | — | — | — | — | — | 49,000Source | 22,000Source | 43,000Source | 9,154,000Source | 43,971,000Source | 52,044,000Source |
Filing attachments
d91010dex991.htm · 8-K · 2026-07-29
EX-99.1 9 d91010dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement July 29, 2026 Combined company to operate as Caldera Therapeutics, developing CLD-423, a potential first-in-class TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease and other immune-mediated diseases Concurrent upsized $278 million private placement committed by a syndicate of leading healthcare institutional investors and…
Read attachment ↗